Clinical trials: Microangiopathy
Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome
TTP and aHUS in Complicated Pregnancies
A single site observational study aiming to: (i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii)…
- Conditions
- Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, Pre-Eclampsia, HELLP Syndrome
- Trial name
- NCT03605511
- Testing
- ADAMTS 13, complement and angiogenic biomarkers
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Type 2 Diabetes Mellitus, Microangiopathy
Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes
This is a prospective and observational study in patients with type two diabetes. The study hypothesis is that chronic hyperglycemia causes an increase in the microcirculation on the carotid artery wall and retina, evaluated by…
- Conditions
- Type 2 Diabetes Mellitus, Microangiopathy, Diabetic Retinopathy, Arteriosclerosis
- Trial name
- OCTAUS-T2D (NCT03594591)
- Testing
- Antidiabetic treatment by usual care
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Clinic of Barcelona
Thrombotic Microangiopathy, Disorder Related to Bone Marrow Transplantation
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Mortality in the major thrombotic microangiopathies (TMAs), TTP and aHUS, exceeds 90% unless rapidly diagnosed and appropriately treated.
- Trial name
- NCT02604420
- Testing
- eculizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Type2 Diabetes Mellitus, Microangiopathy
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke).
- Conditions
- Type2 Diabetes Mellitus, Microangiopathy, Non Alcoholic Fatty Liver Disease, Coronary Artery Disease
- Trial name
- PRECISED (NCT02248311)
- Where
- Spain
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Pre-Eclampsia, Severe, HELLP Syndrome
Promising Bimarker Prediction of Outcome of HELLP Syndrome.
HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia.
- Conditions
- Pre-Eclampsia, Severe, HELLP Syndrome, Microangiopathy
- Trial name
- NCT03246542
- Testing
- shistocytes percentage
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AYMAN ABDELKADER MOHAMED ABDELKADER
Pre-Eclampsia, Severe, HELLP Syndrome
Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome
Immature platelet fraction is a non-invasive test of real time thrombopoiesis. High IPF% has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption.
- Conditions
- Pre-Eclampsia, Severe, HELLP Syndrome, Microangiopathy
- Trial name
- NCT03232359
- Testing
- immature platelets fraction
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- AYMAN ABDELKADER MOHAMED ABDELKADER
Cerebral Microangiopathy, CADASIL
Impact of tDCS on Cerebral Autoregulation
The aim of the study is to investigate whether there is a polarity-specific influence of tDCS on cerebral vasomotor reactivity monitored by transcranial doppler sonography.
- Conditions
- Cerebral Microangiopathy, CADASIL, Migraine With Aura, ICA Stenosis
- Trial name
- NCT01865604
- Testing
- Anodal tDCS, Cathodal tDCS
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Thrombotic Microangiopathy
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
The purpose of this compassionate use study, for two patients with thrombotic microangiopathy, is to provide expanded access to patients who have participated in the clinical trial OMS721-TMA-001 and in whom improvement in their…
- Trial name
- NCT02355782
- Testing
- OMS721
- Sponsor
- Michal Nowicki
Thrombotic Microangiopathies
Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)
Screening of TMA patients for ADAMTS13 activity and the description of systemic organ damage and/or organ failure in different entities of thrombotic microangiopathies (TMA)
- Trial name
- Adamscreen (NCT02373267)
- Testing
- Technozyme
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Thrombotic Microangiopathy, Hemolytic Uremic Syndrome
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Trial name
- NCT00593229
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small…
- Trial name
- NCT00726544
- Testing
- ARC1779 Injection
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 100 people
- Sponsor
- Archemix Corp.